Apr 7, 2024 · Geneos Therapeutics, a Phase 2 biotherapeutics company, is developing DNA-based personalized therapeutic cancer vaccines (PTCVs) which may serve an important role as a new immunotherapeutic paradigm for cancer.

Geneos is currently pursuing clinical development to treat cancer patients with personalized neoantigen-directed therapeutic vaccination.

Dr. Sardesai founded Geneos after building Inovio Pharmaceuticals into a Phase III cancer and infectious disease immunotherapy company serving as its Chief Operating Officer.

Philadelphia, PA – April 7, 2024 – Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCVs), today announced the publication of positive safety, immunogenicity, and efficacy data from the full cohort of patients enrolled in its GT-30 clinical trial in Nature ...

Of the multiple technical solutions offered by Geneos’ GT-EPIC™ platform, the most fundamental is an ability to rapidly deploy a therapeutic construct which does not attempt to outsmart nature in presuming to preselect high value neoantigens; the neoantigen carrying capacity of the platform allows inclusion of all neos in virtually all ...

Dr. Sardesai founded Geneos after building Inovio Pharmaceuticals into a Phase III cancer and infectious disease immunotherapy company serving as its Chief Operating Officer.

Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million — Proceeds Will Fund Completion of GT-30 Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer — — Shanghai-based SHC Added to Geneos’ Investor Syndicate —

Apr 7, 2024 · Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer

Mar 6, 2024 · Geneos Therapeutics, a clinical stage biotherapeutics company, is developing personalized therapeutic cancer vaccines (PTCVs) that may serve an important role in new immunotherapeutic paradigms for cancer.

Jul 8, 2021 · GENEOS PERSONALIZED TREATMENT DRIVES IMMUNE RESPONSES BY DESIGN pIL12 Patient specific optimized multi-neoantigen insert cloned into optimized DNA expression vector + • Personalized product has three components – —Optimized DNA plasmid encoding neoantigens —IL-12 (pIL12): Cytokine immune-modulator; Boosts T cells